Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(60.0%)
Phase 1
1(20.0%)
Phase 2
1(20.0%)
5Total
N/A(3)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07033325Enrolling By Invitation

University-Based Chagas Testing in Salta Province, Argentina

Role: collaborator

NCT05453045Not ApplicableUnknown

Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva

Role: lead

NCT04041427Not ApplicableCompleted

Urine Albendazole Levels for Coverage Assessment

Role: lead

NCT04381884Phase 2Completed

Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19

Role: collaborator

NCT03192449Phase 1Completed

Serum Pharmacokinetic Disposition and Urinary Excretion of Albendazole

Role: lead

NCT01308268Not ApplicableUnknown

Management of Soil-transmitted Helminthiasis and Strongyloidiasis

Role: lead

All 6 trials loaded